Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer

Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer

Background: Osimertinib efficacy in pre-treated patients with epidermal growth factor receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC) has been demonstrated in clinical trials, but real-world data, particularly regarding resistance profile, remains limited. This study aims to analyze...

Full description

Bibliographic Details
Main Authors: Maria Gabriela O. Fernandes, Catarina Sousa, Maria Jacob, Leonor Almeida, Vanessa Santos, David Araújo, Hélder Novais Bastos, Adriana Magalhães, Luís Cirnes, Conceição Souto Moura, Henrique Queiroga, Natália Cruz-Martins, Venceslau Hespanhol
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
EGFR T790M mutation
osimertinib
resistance
real-world data
next generation sequencing
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.602924/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.602924/full

Similar Items